Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer

Research output: Contribution to journalArticle


Background: Studies have shown that Ki-67 response after short-term neoadjuvant aromatase inhibitors may predict recurrence in postmenopausal breast cancer, whereas its prognostic effect in premenopausal women is unknown. Patients and methods: We compared the prognostic and predictive value of baseline and post-treatment Ki-67 in 120 pre-and postmenopausal women with early-stage estrogen receptor-positive breast cancer who participated in a 4-week presurgical trial of tamoxifen. Results: After 7.2 years of follow-up, women with post-treatment Ki-67 in the second (14%-19%), third (20%-29%) and top (≥30%) quartiles had a recurrence hazard ratio of 2.92 [95% confidence interval (CI) 0.95-8.96], 4.37 (1.56-12.25) and 6.05 (2.07-17.65), respectively, as compared with those in the bottom quartile (

Original languageEnglish
Pages (from-to)582-587
Number of pages6
JournalAnnals of Oncology
Issue number3
Publication statusPublished - Mar 2011



  • Breast cancer
  • Ki-67
  • Predictive biomarker
  • Prognostic biomarker
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this